Cogent Biosciences develops targeted drugs for rare, genetically driven diseases, led by bezuclastinib for systemic mastocytosis and GIST. COGT reports earnings on Fri, Nov 6, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in COGT, 0% of them bullish and 100% bearish. In the past 30 days there were 2 dark pool prints.
Prices, price targets and earnings estimates for COGT are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether COGT is in one of them and how their past COGT trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Cogent Biosciences
Cogent Biosciences is a biotechnology company based in Waltham, Massachusetts, that develops drugs for diseases caused by specific genetic mutations. Its lead candidate, bezuclastinib, is being studied for systemic mastocytosis, a rare disease in which mast cells build up in the body, and for gastrointestinal stromal tumors, a cancer of the digestive tract. The company is also developing other targeted therapies, including inhibitors aimed at FGFR2/3 and ErbB2 mutations. Its intended patients are people with rare, genetically driven diseases.
